Article Sidebar
Published:
Jun 18, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of montelukast/budesonide formoterol powder inhalation in chronic obstructive pulmonary disease
Abstract
Purpose: To investigate the clinical efficacy of montelukast/budesonide formoterol powder inhalation in treating chronic obstructive pulmonary disease (COPD) and its impact on serum high-sensitivity Creactive protein (hs-CRP), cancer antigen 125 (CA-125), and interleukin (IL)-6 levels.
Methods: In total, 86 COPD patients treated in the clinic of Department of Respiratory Medicine in
Yichun People’s Hospital between December 2019 and December 2020 were recruited and randomly assigned to group A and group B alternately at the point of admission. Group B received conventional treatment, while group A was treated with conventional treatment plus montelukast/ budesonide formoterol powder inhalation.
Results: Patients receiving montelukast /budesonide formoterol powder inhalation showed lower scores for cough, sputum, and shortness of breath, compared conventional treatment (p < 0.001). Patients in group A showed lower serum levels of hs-CRP, CA-125, and IL-6 after treatment than those in group B (p < 0.05). Pulmonary function and arterial blood gas indices were significantly different between the two groups after treatment (p < 0.05). Montelukast /budesonide formoterol powder inhalation resulted in higher Generic Quality Of Life Inventory-74 (GQOLI-74) scores and 6-min walking distance (6MWD) scores in patients than conventional treatment (p < 0.001). Also, Group A had a lower incidence of adverse reactions than group B (p < 0.05).
Conclusion: Montelukast/budesonide formoterol powder inhalation has a better therapeutic effect versus conventional treatment, and improves patients' lung function and exercise tolerance. Further clinical trials are, however, required prior to general use in clinical practice.
